10x Genomics, Inc. (TXG)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $4.76B
- P/E ratio
- —
- EPS
- —
- Volume
- 2,362,969
- 52-week high
- —
- 52-week low
- —
- Open
- $43.31
- Day high
- $44.20
- Day low
- $41.93
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $642.82M | -$43.54M | -$0.35 |
| 2024 | $610.79M | -$182.63M | -$1.52 |
| 2023 | $618.73M | -$255.1M | -$2.18 |
| 2022 | $516.41M | -$166M | -$1.46 |
| 2021 | $490.49M | -$58.22M | -$0.53 |
About 10x Genomics, Inc.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
- CEO
- Serge Saxonov
- Employees
- 1,306
- Country
- US
- IPO date
- Sep 12, 2019
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is 10x Genomics, Inc.'s stock price today?
- TXG is trading at $43.22 as of Jul 20, 2026.
- What is 10x Genomics, Inc.'s market cap?
- 10x Genomics, Inc. (TXG) has a market capitalization of $4.76B.
- Does 10x Genomics, Inc. pay a dividend?
- 10x Genomics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is 10x Genomics, Inc. in?
- 10x Genomics, Inc. operates in the Healthcare sector.